VICINIUM TRIALS

Past trials

In a Phase I clinical trial with Vicinium™ in patients with bladder cancer, results showed that Vicinium™ was well tolerated in most patients, with the most frequent side effects reported being dysuria (pain or difficulty urinating; 14.1% of patients), hematuria (blood in urine; 10.9% of patients) and fatigue (tiredness; 7.8% of patients),

Exploratory effectiveness was evaluated in the trial with the following findings being reported:

VB4-845-02-I – Phase I Trial

Weekly dosings via intravesical instillation once a week for 6 weeks followed by 6 weeks of no treatment.

Of the 61 Ep-CAM positive patients who were considered evaluable at the end of the trial:

Preliminary results were initially presented at the 42nd Annual Meeting of the American Society of Clinical Oncology. (Abstract #4580). Final results were presented at the 102nd Annual Meeting of the American Urological Association. (Abstract #91750)